Connor Clark & Lunn Investment Management Ltd. Buys 64,872 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 665.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,625 shares of the company's stock after buying an additional 64,872 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.22% of TransMedics Group worth $11,716,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMDX. International Assets Investment Management LLC acquired a new stake in shares of TransMedics Group during the 2nd quarter valued at about $47,000. USA Financial Formulas bought a new position in TransMedics Group during the third quarter worth about $55,000. J.Safra Asset Management Corp grew its stake in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company's stock valued at $67,000 after purchasing an additional 383 shares during the period. Signaturefd LLC raised its holdings in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company's stock worth $67,000 after buying an additional 93 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock worth $76,000 after buying an additional 316 shares during the period. Institutional investors own 99.67% of the company's stock.

TransMedics Group Trading Down 4.2 %

Shares of TransMedics Group stock traded down $3.30 during trading on Friday, reaching $76.04. 2,521,080 shares of the company were exchanged, compared to its average volume of 990,581. The business has a 50-day moving average price of $120.68 and a 200-day moving average price of $138.09. The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of 79.26 and a beta of 2.08. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a twelve month low of $67.77 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company's revenue for the quarter was up 63.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.12) earnings per share. Sell-side analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the sale, the insider now owns 21,105 shares in the company, valued at approximately $3,714,902.10. The trade was a 32.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Tamer I. Khayal sold 2,958 shares of the firm's stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the transaction, the insider now directly owns 20,843 shares of the company's stock, valued at $3,089,766.32. This represents a 12.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,958 shares of company stock valued at $5,230,528. 7.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on TMDX. Baird R W upgraded TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. JPMorgan Chase & Co. lowered their target price on shares of TransMedics Group from $173.00 to $116.00 and set an "overweight" rating on the stock in a report on Tuesday, October 29th. TD Cowen dropped their target price on shares of TransMedics Group from $175.00 to $120.00 and set a "buy" rating for the company in a research report on Monday. Robert W. Baird reduced their price target on shares of TransMedics Group from $200.00 to $150.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 29th. Finally, Needham & Company LLC reiterated a "hold" rating and set a $109.00 price target on shares of TransMedics Group in a research report on Friday. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $131.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.